ZENOBIA THERAPEUTICS
Zenobia Therapeutics was founded in 2008 with a focus on discovering treatments for neurodegenerative diseases using fragment-based lead discovery. In 2014, Zenobia added a products division, Zenobia Fragments that supplies products and services to support fragment-based lead discovery.
ZENOBIA THERAPEUTICS
Industry:
Biotechnology Pharmaceutical
Founded:
2008-01-01
Address:
San Diego, California, United States
Country:
United States
Website Url:
http://www.zenobiatherapeutics.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
225 K USD
Technology used in webpage:
Google Google Cloud Wix
Similar Organizations
Aclipse Therapeutics
Aclipse Therapeutics focuses on developing differentiated drugs to address diseases with unmet medical needs.
Aperture Therapeutics
Aperture Therapeutics develops novel therapies for neurodegenerative diseases, leveraging genetic diversity.
Lysosomal Therapeutics
Lysosomal Therapeutics deliver cures for neurodegenerative diseases.
NephroDI Therapeutics
NephroDI Therapeutics is a biopharmaceutical company that focuses on the concentration disorders of the kidney.
Current Employees Featured
Founder
Investors List
National Science Foundation
National Science Foundation investment in Grant - Zenobia Therapeutics
Official Site Inspections
http://www.zenobiatherapeutics.com
- Host name: unalocated.63.wixsite.com
- IP address: 185.230.63.186
- Location: Ashburn United States
- Latitude: 39.018
- Longitude: -77.539
- Metro Code: 511
- Timezone: America/New_York
- Postal: 20147
More informations about "Zenobia Therapeutics"
Home | Zenobia Therapeutics
[email protected]. 3550 General Atomics Court San Diego, CA 92121 ©2016 BY ZENOBIA THERAPEUTICS. PROUDLY CREATED WITH WIX.COM. bottom of page ...See details»
Zenobia Therapeutics - Crunchbase Company Profile & Funding
Contact Email [email protected] Zenobia Therapeutics was founded in 2008 with a focus on discovering treatments for neurodegenerative diseases using fragment-based lead …See details»
Zenobia Therapeutics Company Profile 2024: Valuation, Funding ...
Zenobia Therapeutics General Information Description. Developer of fragment products intended to treat neurodegenerative diseases. The company's medical treatments use fragment-based …See details»
Zenobia Therapeutics, Inc. Company Profile | San Diego, CA ...
Find company research, competitor information, contact details & financial data for Zenobia Therapeutics, Inc. of San Diego, CA. Get the latest business insights from Dun & Bradstreet.See details»
Zenobia Therapeutics, Inc.: Drug pipelines, Patents, Clinical trials ...
Jun 17, 2023 Explore Zenobia Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 8 literature, Drug:G-2019S LRRK2 program (Zenobia Therapeutics).See details»
Zenobia Therapeutics Company Profile | Management and
[email protected]: Zenobia Therapeutics Top Competitors. Company Employees Revenue Top technologies; Structure Based Design Inc. 9: $1.2 M: Creative BioLabs. 36: $4.3 …See details»
ZENOBIA THERAPEUTICS - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for ZENOBIA THERAPEUTICS of San Diego, CA. Get the latest business insights from Dun & Bradstreet.See details»
Zenobia Therapeutics - Overview, News & Similar companies
Zenobia Therapeutics contact info: Phone number: (858) 926-5780 Website: www.zenobiatherapeutics.com What does Zenobia Therapeutics do? Zenobia Therapeutics …See details»
Zenobia Therapeutics - VentureRadar
Offers treatment discovery for neurodegenerative diseases through fragment-based lead discovery, internal CNS research programs, and support services for various global targets. "See details»
Zenobia Therapeutics - Company Profile - Tracxn
Oct 20, 2024 Zenobia Therapeutics - Using fragment-based lead discovery to identify small molecules for the treatment of Parkinson's, Huntington's and Alzheimer's disease.. Raised …See details»
Zenobia Therapeutics | VentureRadar
Website: https://www.zenobiatherapeutics.com/ Offers treatment discovery for neurodegenerative diseases through fragment-based lead discovery, internal CNS research ...See details»
Zenobia Therapeutics - Craft
Zenobia Therapeutics has 1 employees at their 1 location. See insights on Zenobia Therapeutics including office locations, competitors, revenue, financials, executives, subsidiaries and more …See details»
Zenobia Therapeutics - Products, Competitors, Financials, …
Zenobiatherapeutics.com. Overview & Products; Financials; Founded Year 2008. Stage Grant - II | Alive. Total Raised $1.23M. Last Raised $1M | 1 yr ago. About Zenobia Therapeutics. Zenobia …See details»
Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based …
Jul 21, 2008 Zenobia Therapeutics, Inc. Begins Operations as a Fragment-Based Lead Discovery Company LA JOLLA, Calif., July 21 /PRNewswire/ -- Zenobia Therapeutics, Inc. …See details»
Zenobia Therapeutics, Inc. Successfully Completes Initial
LA JOLLA, Calif., April 14 /PRNewswire/ -- Zenobia Therapeutics, Inc., the leader in fragment-based lead discovery for diseases of the central nervous system, announced successful …See details»
Award - SBIR
Official websites use .gov A .gov website belongs to an official government organization in the United States. Secure .gov websites use HTTPS A lock ... [email protected]. …See details»
Zenobia Therapeutics Begins Operations as a Fragment Based …
Jul 24, 2008 Zenobia Therapeutics, Inc. announced that they have initiated research at their facility in La Jolla, California. Zenobia was founded June 1, 2008, is privately funded and …See details»
Zenobia Therapeutics Announce A Partnership With The …
LA JOLLA, Calif., Aug. 14, 2012 /PRNewswire/ -- Zenobia Therapeutics, the leader in fragment-based lead discovery for CNS disease announce today a strategic partnership to provide …See details»
Home | zenfragments-copy
Libraries are pre-plated in 96 well format and shipped as dry film. Just add solvent and start screening! Compounds are pre-tested for solubility and soluble in DMSO or water at 200mM …See details»